Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

14.32
+0.30002.14%
Post-market: 14.730.4100+2.86%19:35 EDT
Volume:235.87K
Turnover:3.37M
Market Cap:1.84B
PE:-19.46
High:14.42
Open:14.08
Low:14.07
Close:14.02
52wk High:21.50
52wk Low:9.61
Shares:128.30M
Float Shares:78.65M
Volume Ratio:0.55
T/O Rate:0.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7359
EPS(LYR):-0.8457
ROE:-18.22%
ROA:-6.16%
PB:3.20
PE(LYR):-16.93

Loading ...

Mesoblast Director Increases Shareholding Through Option Exercise

TIPRANKS
·
Oct 28, 2025

Mesoblast Limited Releases 2025 Corporate Governance Statement

TIPRANKS
·
Oct 27, 2025

Mesoblast's Fiscal Q2 Ryoncil Revenue Rises 66%

MT Newswires Live
·
Oct 20, 2025

Mesoblast Sees 69% Revenue Surge for Ryoncil® Amid Expanding Market Reach

TIPRANKS
·
Oct 20, 2025

BRIEF-Mesoblast Posts Quarter Revenue From Cell Therapy Products $20.6 Million

Reuters
·
Oct 20, 2025

Mesoblast Says Fiscal Q1 Cell Therapy Sales Rises More Than Tenfold

MT Newswires Live
·
Oct 20, 2025

Mesoblast Ltd - Qtr Revenue From Cell Therapy Products US$20.6 Mln

THOMSON REUTERS
·
Oct 20, 2025

JPMorgan Chase & Co. Ceases Substantial Holding in Mesoblast Limited

TIPRANKS
·
Oct 15, 2025

Mesoblast Limited Announces Cessation of Securities

TIPRANKS
·
Oct 14, 2025

Mesoblast Limited to Quote 3 Million New Securities on ASX

TIPRANKS
·
Oct 14, 2025

Mesoblast to Complete Ryoncil Treatment in Fiscal Year 2026 on 63 Patients, Jefferies Says

MT Newswires Live
·
Oct 13, 2025

Maxim Group Reaffirms Their Buy Rating on Mesoblast (MESO)

TIPRANKS
·
Oct 09, 2025

Mesoblast Ltd : Piper Sandler Raises Target Price to $35 From $24

THOMSON REUTERS
·
Oct 07, 2025

Mesoblast Reports $21.9 Million Ryoncil Sales Revenue; Shares Up 8%

MT Newswires Live
·
Oct 07, 2025

Mesoblast Reports 66% Revenue Surge for Ryoncil in Second Quarter

TIPRANKS
·
Oct 07, 2025

Mesoblast reports Q2 Ryoncil revenue up 66% y/y

TIPRANKS
·
Oct 07, 2025

Mesoblast Shares Are Rising Higher: What's Behind The Move?

Benzinga
·
Oct 04, 2025

Mesoblast’s Ryoncil® Gains Medicare & Medicaid J-Code for Enhanced Access

TIPRANKS
·
Oct 03, 2025

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

GlobeNewswire
·
Oct 03, 2025

Mesoblast’s U.S. Origin Designation Shields Products from Tariffs

TIPRANKS
·
Sep 29, 2025